DK3365368T3 - Tgfbeta1-bindende immunoglobuliner og anvendelse deraf - Google Patents

Tgfbeta1-bindende immunoglobuliner og anvendelse deraf Download PDF

Info

Publication number
DK3365368T3
DK3365368T3 DK17716332.6T DK17716332T DK3365368T3 DK 3365368 T3 DK3365368 T3 DK 3365368T3 DK 17716332 T DK17716332 T DK 17716332T DK 3365368 T3 DK3365368 T3 DK 3365368T3
Authority
DK
Denmark
Prior art keywords
tgfbeta1
binding immunoglobulins
immunoglobulins
binding
Prior art date
Application number
DK17716332.6T
Other languages
English (en)
Inventor
Thomas Schurpf
Gregory J Carven
Abhishek Datta
Kimberly Long
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58503696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3365368(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Application granted granted Critical
Publication of DK3365368T3 publication Critical patent/DK3365368T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK17716332.6T 2016-03-11 2017-03-10 Tgfbeta1-bindende immunoglobuliner og anvendelse deraf DK3365368T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662307353P 2016-03-11 2016-03-11
US201762443615P 2017-01-06 2017-01-06
US201762452866P 2017-01-31 2017-01-31
PCT/US2017/021972 WO2017156500A1 (en) 2016-03-11 2017-03-10 Tgfb1-binding immunoglobulins and use thereof

Publications (1)

Publication Number Publication Date
DK3365368T3 true DK3365368T3 (da) 2023-06-26

Family

ID=58503696

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17716332.6T DK3365368T3 (da) 2016-03-11 2017-03-10 Tgfbeta1-bindende immunoglobuliner og anvendelse deraf

Country Status (19)

Country Link
US (2) US11643459B2 (da)
EP (2) EP3365368B1 (da)
JP (4) JP2019509737A (da)
KR (2) KR20180122397A (da)
CN (1) CN109071646A (da)
AU (2) AU2017230103A1 (da)
BR (1) BR112018068340A2 (da)
CA (1) CA3055555A1 (da)
DK (1) DK3365368T3 (da)
EA (1) EA201891909A1 (da)
ES (1) ES2951648T3 (da)
FI (1) FI3365368T3 (da)
HU (1) HUE062976T2 (da)
IL (2) IL307835A (da)
MX (1) MX2018010948A (da)
PL (1) PL3365368T3 (da)
PT (1) PT3365368T (da)
SG (1) SG11201807176XA (da)
WO (1) WO2017156500A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3365368B1 (en) 2016-03-11 2023-05-17 Scholar Rock, Inc. Tgfbeta1-binding immunoglobulins and use thereof
CR20190350A (es) 2017-01-06 2019-11-15 Scholar Rock Inc INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CN110573161A (zh) * 2017-03-28 2019-12-13 勃林格殷格翰国际有限公司 用于治疗肌营养不良的方法的尼达尼布
HUE063120T2 (hu) 2017-05-09 2023-12-28 Scholar Rock Inc LRRC33-inhibitorok és alkalmazásuk
US20200231682A1 (en) 2017-07-28 2020-07-23 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
US20210115122A1 (en) * 2018-02-23 2021-04-22 Chugai Seiyaku Kabushiki Kaisha Cross-species anti-latent tgf-beta 1 antibodies and methods of use
AU2019302679A1 (en) 2018-07-11 2021-02-11 Scholar Rock, Inc. High-affinity, isoform-selective TGFbeta1 inhibitors and use thereof
EP3677278B1 (en) 2018-07-11 2021-11-10 Scholar Rock, Inc. Isoform selective tgfbeta1 inhibitors and use thereof
TW202019957A (zh) 2018-07-11 2020-06-01 美商供石公司 TGFβ1抑制劑及其用途
CN113164780A (zh) 2018-10-10 2021-07-23 泰洛斯治疗公司 抗lap抗体变体及其用途
MX2021009175A (es) * 2019-01-30 2021-09-14 Scholar Rock Inc Inhibidores especificos del complejo de ltbp de tgf? y usos de los mismos.
AU2020340176A1 (en) * 2019-08-28 2022-04-14 Chugai Seiyaku Kabushiki Kaisha Cross-species anti-latent TGF-beta 1 antibodies and methods of use
CA3166328A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
TW202135862A (zh) 2020-01-11 2021-10-01 美商供石公司 TGFβ抑制劑及其用途
EP4279509A1 (en) * 2021-01-18 2023-11-22 Shanghai Jemincare Pharmaceuticals Co., Ltd. Garp protein antibody and application thereof
JP7280400B2 (ja) * 2021-02-26 2023-05-23 中外製薬株式会社 種交差性抗潜在型TGF-β1抗体の使用
WO2022180764A1 (en) 2021-02-26 2022-09-01 Chugai Seiyaku Kabushiki Kaisha Uses of cross-species anti-latent tgf-beta 1 antibodies
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022206753A1 (zh) * 2021-03-29 2022-10-06 山东先声生物制药有限公司 GARP/TGFβ1抗体及其应用
EP4348260A2 (en) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof
WO2023192895A1 (en) 2022-03-29 2023-10-05 Allogene Therapeutics Inc. Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
WO2024023283A1 (en) 2022-07-29 2024-02-01 Institut National de la Santé et de la Recherche Médicale Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK1820858T3 (da) 1991-03-01 2009-11-02 Dyax Corp Kimært protein omfatende mikroprotein med to eller flere disulfidbindinger og udförelsesformer deraf
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
CA2250166A1 (en) 1996-03-28 1997-10-02 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
CN1451043A (zh) 2000-06-29 2003-10-22 艾博特公司 双特异性抗体及其制备方法和用途
GB0230202D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Ligand
JP4653660B2 (ja) * 2003-09-04 2011-03-16 独立行政法人理化学研究所 TGF−β活性化制御領域の切断面を認識する抗体
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
LT1850873T (lt) * 2005-02-08 2019-04-10 Genzyme Corporation Antikūnas prieš tgf beta
RS51845B (en) * 2005-04-22 2012-02-29 Eli Lilly And Company SPECIFIC TGF BETA 1 ANTIBODIES
EP3524626A1 (en) 2007-03-22 2019-08-14 Biogen MA Inc. Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
MX2010013236A (es) 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
JO3096B1 (ar) 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
WO2011102483A1 (ja) * 2010-02-19 2011-08-25 独立行政法人理化学研究所 ヒトTGF-βのLAPに結合する抗体
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
TWI531377B (zh) 2011-02-08 2016-05-01 艾伯維有限公司 骨關節炎及疼痛之治療
KR102046666B1 (ko) 2011-05-25 2019-11-19 이나뜨 파르마 염증성 장애의 치료를 위한 항-kir 항체
EP2714735B1 (en) 2011-06-03 2021-07-21 XOMA Technology Ltd. Antibodies specific for tgf-beta
RU2708977C2 (ru) 2011-06-10 2019-12-12 МЕДИММЬЮН, ЭлЭлСи Молекулы, связывающиеся с psl pseudomonas, и пути их применения
EP2766033B1 (en) 2011-10-14 2019-11-20 Novartis AG Antibodies and methods for wnt pathway-related diseases
CA2856149A1 (en) 2011-11-08 2013-05-16 Pfizer Inc. Methods of treating inflammatory disorders using anti-m-csf antibodies
RS56796B1 (sr) 2011-11-14 2018-04-30 Regeneron Pharma Kompozicije i postupci za uvećanje mišićne mase i jačine mišića specifičnim antagonizovanjem gdf8 i/ili aktivina a
US9518112B2 (en) 2012-03-08 2016-12-13 Ludwig Institute For Cancer Research Ltd TGF-β1 specific antibodies and methods and uses thereof
CA2890733A1 (en) 2012-11-06 2014-05-15 Scholar Rock, Inc. Compositions and methods for modulating cell signaling
CN105283196B (zh) 2013-03-15 2018-10-12 贝丝以色列女执事医疗中心 用于产生和使用构象-特异性抗体的方法和组合物
WO2014182676A2 (en) 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
MX2016001356A (es) * 2013-08-01 2016-10-26 Ludwig Inst For Cancer Res Ltd Proteina anti-garp y sus usos.
EP2832747A1 (en) * 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
CA2947967A1 (en) 2014-05-06 2015-11-12 Scholar Rock, Inc. Compositions and methods for growth factor modulation
ES2843277T3 (es) 2014-06-26 2021-07-16 Heidelberg Immunotherapeutics Gmbh Aplicación tópica para un anticuerpo anti-VHS
WO2016079157A1 (en) 2014-11-18 2016-05-26 Institut Pasteur Polyclonal antibodies specific for serogroup x of n. meningitidis and uses thereof in diagnosis
CA2973978A1 (en) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-lap monoclonal antibodies
TWI733661B (zh) * 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子-β1的經修飾IgG抗體
EP3365368B1 (en) * 2016-03-11 2023-05-17 Scholar Rock, Inc. Tgfbeta1-binding immunoglobulins and use thereof
EP3484499A4 (en) 2016-07-14 2020-05-13 Scholar Rock, Inc. ANTI-TGFB ANTIBODIES, METHODS AND USES
CR20190350A (es) 2017-01-06 2019-11-15 Scholar Rock Inc INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS

Also Published As

Publication number Publication date
FI3365368T3 (fi) 2023-06-13
CA3055555A1 (en) 2017-09-14
WO2017156500A8 (en) 2018-01-25
US20190071493A1 (en) 2019-03-07
SG11201807176XA (en) 2018-09-27
WO2017156500A1 (en) 2017-09-14
AU2017230103A1 (en) 2018-09-06
EP4169942A1 (en) 2023-04-26
US11643459B2 (en) 2023-05-09
AU2024202692A1 (en) 2024-05-30
US20230348583A1 (en) 2023-11-02
JP2022031403A (ja) 2022-02-18
CN109071646A (zh) 2018-12-21
BR112018068340A2 (pt) 2019-01-15
IL261442A (en) 2018-10-31
KR20180122397A (ko) 2018-11-12
JP2019509737A (ja) 2019-04-11
MX2018010948A (es) 2019-06-20
IL307835A (en) 2023-12-01
JP2023108057A (ja) 2023-08-03
ES2951648T3 (es) 2023-10-24
HUE062976T2 (hu) 2023-12-28
EP3365368B1 (en) 2023-05-17
PT3365368T (pt) 2023-08-17
EA201891909A1 (ru) 2019-02-28
PL3365368T3 (pl) 2023-08-21
JP2022028680A (ja) 2022-02-16
EP3365368A1 (en) 2018-08-29
KR20230088508A (ko) 2023-06-19
WO2017156500A9 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
DK3365368T3 (da) Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
DK3504242T3 (da) Anti-ox40-antistoffer og anvendelse deraf
DK3443009T3 (da) Anti-tim-3-antistoffer og sammensætninger
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3258951T3 (da) Anti-pvrig antistoffer og fremgangsmåder for anvendelse
DK3333191T3 (da) Anti-C10ORF54-antistoffer og anvendelser deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3480213T3 (da) Syntac-polypeptider og anvendelser deraf
DK3463435T3 (da) Alpha-synuklein-antistoffer og anvendelser deraf
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
DK3265641T3 (da) Stigørenhed og fremgangsmåde
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3445785T3 (da) Humaniserede anti-clever-1-antistoffer og anvendelse deraf
DK3359563T3 (da) Antigenreceptorer og anvendelser deraf
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
MA49905A (fr) Polyesteramines et polyesterquats
DK3448419T3 (da) Interferon-beta-antistoffer og anvendelser deraf
DK3417058T3 (da) Sortase-modificerede molekyler og anvendelser deraf
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf